Japan's steady surge in pharmaceutical imports: A story of demographic resilience and market stability

Kim Pedersen
Dec 26, 2025
5 min read

Updated: Dec 27, 2025

Written by: Kim Pedersen 2025/12/26

Japan's steady surge in pharmaceutical imports: A story of demographic resilience and market stability

Geopolitical tensions

In a world where trade flows often swing wildly due to geopolitical tensions or environmental mandates, Japan's imports of medicaments under HS3004 stand out as a beacon of consistency.

From 2015 to 2025, these imports, covering everything from mixed therapeutic drugs to prophylactic treatments, have grown steadily, with values climbing from around 3 trillion JPY in 2015 to over 4.5 trillion JPY by 2024, based on recent Ministry of Finance data. Volume metrics tell a similar tale of expansion, hovering at billions of kilograms annually, with a notable post-2020 acceleration driven by global supply chain adaptations and domestic health needs. This growth aligns closely with the provided statistics, showing stable yet upward trends in both value and volume, confirming the article's narrative of resilience amid an aging society.

The demographic driver: Japan's super-aged society

At the heart of this expansion is Japan's demographic reality. In 2000, just 17.4% of the population was over 65; by 2025, that figure has reached 29%, encompassing around 36 million seniors. This super-aged society has intensified demand for medicaments targeting chronic conditions like hypertension, diabetes, and osteoporosis. Trade data from the last decade reveals a clear correlation: HS3004 imports rose at 5-10% annually pre-2020, then accelerated with peaks in volume during the pandemic years, as healthcare systems ramped up to handle increased vulnerabilities. The attached charts validate this, with aggregate import volumes showing consistent highs, particularly from 2020 onward, underscoring Japan's proactive import strategy to support universal healthcare without major disruptions.

Key trends in subcodes and dramatic shifts

Diving into HS9 subcodes, the data highlights nuanced shifts. For instance, 300490 (other medicaments, including generics for everyday therapies) dominates in volume, reflecting Japan's emphasis on cost-effective solutions for widespread elderly care. Meanwhile, 300439 (hormones and related products, often for endocrine and age-related treatments) has seen dramatic growth, with import volumes surging from low levels pre-2015 to over 30,000 KG monthly peaks by 2025 in the provided Danish-specific graphs. This spike aligns with global innovations in GLP-1 receptor agonists, drugs like semaglutide, used for diabetes management and, increasingly, weight control. These have exhibited the highest relative changes, with 20-30% annual growth since 2020, driven by evolving medical protocols and rising metabolic health concerns.

Line graph, box diagram and donut chart of HS3004 medicaments import to Japan from 1999 to 2025.

The Danish pivot: Novo Nordisk's transformation

A compelling subplot emerges with Danish pharmaceutical leader Novo Nordisk, illustrating how individual companies can redefine bilateral trade. Traditionally, Novo exported insulin (under HS300431) to Japan, with volumes remaining relatively stable or slightly declining in recent years, as shown in the below graph, peaking around 2018-2020 before leveling off. However, the real transformation lies in semaglutide-based products (Ozempic for diabetes, Wegovy for obesity), which have propelled HS300439 imports from Denmark upward dramatically since 2020. By 2024, Novo's sales in Japan grew 3.6%, largely fueled by semaglutide demand, contributing to Denmark's pharmaceutical exports outpacing traditional sectors.

Indeed, the graphs confirm this pivot: while insulin holds steady, hormone-related volumes explode, reflecting Novo's global strategy shift toward multifunctional therapies.

From pork to medicine

This evolution has reshaped Denmark's overall exports to Japan. Once celebrated for pork under HS0203, worth hundreds of billions of JPY annually, Denmark's pharmaceutical shipments (HS30xx, including HS3004) now dwarf them, with values significantly higher in recent years. The attached data supports this understanding, showing Denmark's targeted surge in high-value medicaments, turning a food-exporting nation into a life-sciences powerhouse. It's a quirky economic twist: the bacon exporters are now saving lives with cutting-edge drugs.

Solving the paradox: Why obesity drugs in lean Japan?

Yet, this begs the question: why such demand for obesity-linked medications in Japan, where obesity rates remain low at about 4.5% of adults, far below global averages, and elderly citizens rarely face weight issues? The provided statistics and broader data reveal it's not primarily about obesity per se. Instead, these drugs address type 2 diabetes, affecting 1 in 10 Japanese adults (over 11 million projected by 2030), often through metabolically unhealthy normal weight (MUNW) profiles, where 9.35% of normal-BMI individuals show diabetes risks. Among younger generations (20-50s), rising Western diets, sedentary lifestyles, and urban stress have driven BMI increases of 10-15% over the decade, boosting preventive use.

Expatriates and foreign residents (over 3 million) add diversity, with higher obesity rates in some groups fueling off-label prescriptions. Policy plays a role too: Japan's 2023 approval of Wegovy and public health campaigns promote early intervention, reducing stigma and encouraging metabolic health focus in a thinness-prioritizing culture.

The global supply chain: Who leads and why

The top exporters to Japan under HS3004, China (21.01% of volume), the US (20.5%), Singapore (10.79%), Thailand (9.46%), and the UK, each bring unique strengths, as evidenced by the below aggregate charts. China leads in high-volume generics and active pharmaceutical ingredients (APIs), serving as the "pharmacy of the world" for affordable bulk drugs essential to Japan's cost-conscious elderly care. The US excels in innovative biopharmaceuticals and high-end therapies, leveraging deep R&D ties and integrated supply chains for cutting-edge treatments. Singapore acts as a regional manufacturing hub for Western firms, with its "gold standard" facilities enabling efficient, high-quality exports of refined medicaments. Thailand's growth stems from its role in Southeast Asian generic production, offering competitive pricing for standard therapies. The UK provides specialized products like respiratory and oncology drugs, supported by historical trade links and expertise in complex formulations. These patterns match the volume-focused data, where lower-value, high-quantity shipments from Asia complement premium imports from the West.

Resilience amid global uncertainty

This isn't a story of chaos or forced pivots. Unlike sectors grappling with CO2 emission crackdowns, where imports of coal (HS2701) or petroleum (HS2710) have fluctuated amid sustainability pressures, pharmaceuticals remain insulated. Japan's universal healthcare system, bolstered by the Pharmaceutical and Medical Device Act, prioritizes reliability over radical changes. Imports from these stable partners ensure no major shortages, even during global crunches like 2020-2022.

Opportunities for exporters

For businesses eyeing Japan, this stability spells opportunity. Exporters of HS3004 products can tap into a market driven by predictable demographic needs, not external "hysteria." As Japan ages gracefully, these imports prove that some markets thrive by evolving steadily, with innovative twists like Novo Nordisk's adding layers of intrigue.

Go deeper than headlines. Work with the data yourself

All observations in this article are based on Japan’s official trade statistics (Ministry of Finance), explored and visualised through JapanTradeStatistics.com.

The platform (japantradestatistics.com) allows you to:

Download trade data for any HS4s you wish.
Drill down into specific HS4 codes, analyzing the data
Instant chart creation (Many variations) Line-, bar-, doughnut-, accumulated-, 100% bars-, box-, YTD and map chats. Check chart types available here.
Compare countries, time periods, and shift in supplier countries
Identify structural trends vs temporary noise (data from 1999 and to today)
Create presentation-ready charts in just minutes, always using the latest available data
Export charts directly into PowerPoint, ensuring your presentation has real time data

If you want to explore other HS4s, focus on specific countries, or test alternative scenarios, you can do this yourself using the platform, quickly, precisely, and without waiting for custom reports.

No time-consuming import of data,
no messing with excel,
just select and you have your chart instantly.

Check out our YouTube to see how easy it is here: https://www.youtube.com/@JapanTradeStatistics

For users who need tailored insights, I also provide:

Custom chart creation on request
HS-level market analysis (please accept partially AI generated analysis)
You are welcome to ask for any other service you might think we can offer

👉 Explore the data yourself at:

https://www.japantradestatistics.com/import/hs3004/

For analyzing yourself, you need to become member (500 JPY + VAT / month) and purchase a HS4 dataset (500 JPY +VAT / month). You can at any time cancel your membership and HS4 dataset easily.